Nicholas Investment Partners LP Sells 77,647 Shares of argenx SE (NASDAQ:ARGX)

Nicholas Investment Partners LP trimmed its position in shares of argenx SE (NASDAQ:ARGX - Free Report) by 83.0% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 15,919 shares of the company's stock after selling 77,647 shares during the quarter. Nicholas Investment Partners LP's holdings in argenx were worth $6,056,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of ARGX. Jennison Associates LLC increased its holdings in argenx by 32.2% during the third quarter. Jennison Associates LLC now owns 1,511,745 shares of the company's stock valued at $743,219,000 after buying an additional 368,367 shares during the last quarter. Massachusetts Financial Services Co. MA grew its holdings in argenx by 1.7% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 591,666 shares of the company's stock worth $225,087,000 after acquiring an additional 10,080 shares in the last quarter. RTW Investments LP lifted its position in shares of argenx by 5.2% in the 3rd quarter. RTW Investments LP now owns 507,195 shares of the company's stock worth $249,352,000 after purchasing an additional 25,000 shares during the period. Invesco Ltd. boosted its position in argenx by 377.0% during the 3rd quarter. Invesco Ltd. now owns 430,787 shares of the company's stock valued at $211,788,000 after acquiring an additional 340,482 shares in the last quarter. Finally, Federated Hermes Inc. grew its position in shares of argenx by 7.4% in the 4th quarter. Federated Hermes Inc. now owns 356,507 shares of the company's stock worth $135,626,000 after buying an additional 24,416 shares during the last quarter. 60.32% of the stock is currently owned by institutional investors.

argenx Price Performance

ARGX traded up $20.95 during trading hours on Wednesday, reaching $376.96. The company's stock had a trading volume of 344,655 shares, compared to its average volume of 313,900. The stock has a market cap of $22.40 billion, a PE ratio of -66.60 and a beta of 0.67. argenx SE has a fifty-two week low of $327.73 and a fifty-two week high of $550.76. The business's 50-day moving average is $381.37 and its 200-day moving average is $407.16.

argenx (NASDAQ:ARGX - Get Free Report) last announced its quarterly earnings results on Monday, May 13th. The company reported ($1.04) earnings per share for the quarter, missing analysts' consensus estimates of ($0.71) by ($0.33). The company had revenue of $412.51 million for the quarter, compared to analyst estimates of $404.03 million. argenx had a negative net margin of 22.58% and a negative return on equity of 14.14%. During the same quarter in the prior year, the business earned ($0.52) earnings per share. Analysts expect that argenx SE will post -2.4 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on ARGX. JPMorgan Chase & Co. lowered their price objective on argenx from $560.00 to $500.00 and set an "overweight" rating for the company in a research report on Monday. Wedbush reissued an "outperform" rating and set a $521.00 price target on shares of argenx in a research report on Thursday, April 18th. Truist Financial increased their target price on shares of argenx from $370.00 to $440.00 and gave the stock a "buy" rating in a research note on Tuesday, March 5th. Scotiabank increased their price objective on shares of argenx from $402.00 to $408.00 and gave the company a "sector perform" rating in a report on Tuesday, March 26th. Finally, Robert W. Baird cut their target price on shares of argenx from $505.00 to $490.00 and set an "outperform" rating for the company in a research note on Friday, March 1st. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, argenx presently has an average rating of "Moderate Buy" and an average target price of $524.68.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.

Want to see what other hedge funds are holding ARGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for argenx SE (NASDAQ:ARGX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.